Gene therapy treatment Luxturna accepted for use in Scotland
Retina UK is delighted that the Scottish Medicines Consortium (SMC) has accepted the gene therapy Luxturna (voretigene neparvovec) for ongoing use by the NHS in Scotland.
Search
Search results
Webinar: Ask the Expert: Dr Roly Megaw
This time we are joined by Roly Megaw, Clinical Lecturer and Honorary Consultant Ophthalmologist at University of Edinburgh and NHS Lothian
Genetics and gene therapy
When we talk about gene therapy we are usually referring to use of a harmless virus, called a vector, to deliver a normal copy of a defective gene into the cells of the eye.
Study of substances in blood suggests choroideremia is not just an isolated eye disease
Choroideremia is a rare genetic condition resulting in progressive sight loss in men.
Information and support
Are you affected by inherited sight loss? We are here to help.
Birthday Fundraising
Mark your special day, whilst fundraising for people with inherited sight loss.
Our Partners
We are proud to work collaboratively with a number of corporate partners to enable our community to live fulfilled lives today as well as supporting the pharmaceutical industry in their mission to develop potential new treatments.
Taking part in the 2021 Virtual London Marathon
Caryn talks about her experience taking part in the 2021 Virtual London Marathon.
Who we are
Retina UK is a charity. Our Board of Trustees is responsible for the strategic management of the organisation and delivery of our charitable objectives.